Daewoong to maximize Olmetec sales

Daewoong Pharm and Daiichi Sankyo Korea plan to co-promote Olmetec (olmesartan medoxomi), a selective AT1 subtype angiotensin II receptor antagonist, from April 1. Olmetec, a prodrug, is hydrolyzed to olmesartan during absorption from the gastrointestinal tract.

Through this strategic co-promotion campaign titled Double Hit Co-Promotion toward hospitals with over 100 beds, both companies are...